NGI226
/ Novartis
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
December 03, 2025
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
(clinicaltrials.gov)
- P2 | N=45 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting
Enrollment closed
March 06, 2025
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
(clinicaltrials.gov)
- P2 | N=46 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jul 2025 ➔ Dec 2025 | Trial primary completion date: Jul 2025 ➔ Dec 2025
Trial completion date • Trial primary completion date
June 23, 2023
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
(clinicaltrials.gov)
- P2 | N=53 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting
Enrollment open
November 28, 2022
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
(clinicaltrials.gov)
- P2 | N=53 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Oct 2024 ➔ Feb 2025 | Initiation date: Oct 2022 ➔ Feb 2023 | Trial primary completion date: Oct 2024 ➔ Feb 2025
Trial completion date • Trial initiation date • Trial primary completion date
October 25, 2022
A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
(clinicaltrials.gov)
- P2 | N=53 | Not yet recruiting | Sponsor: Novartis Pharmaceuticals
New P2 trial
1 to 5
Of
5
Go to page
1